Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Accesswire
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral DrugsKELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada's premier federally funded research organization, the National Research Council ("NRC").The NRC has successfully confirmed Lexaria's study objectives, demonstrating DehydraTECH™ processing and formulation technology does not create a covalently bonded new molecular entity ("NME") and that each drug tested remained stable and did not undergo change in chemical structure. The five drugs studied were remdesivir, ebastine, bepridil, rupintrivir and colchicine, which have antiviral effects through a variety of different modes of action.These findings are strongly supportive of accelerated regulatory filings such as the
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyAccesswire
- Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 DrugsAccesswire
- Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance [Yahoo! Finance]Yahoo! Finance
LEXX
Analyst Actions
- 3/5/24 - Maxim Group
LEXX
Sec Filings
- 5/10/24 - Form 4
- 5/10/24 - Form 4
- 5/10/24 - Form 4
- LEXX's page on the SEC website